Innovative Solutions for the Toughest Environmental Problems
We Make Life Better
About BioLargo
BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact.
BioLargo Companies and Technologies
President & CEO:
Dennis P. Calvert
BioLargo, Inc. (OTCQB:BLGO) supports four subsidiaries that develop and commercialize cleantech products and specialty services. BioLargo holds the intellectual property for each technology and product.
President:
Dr. Richard Smith
Flagship product:
The Advanced Oxidation System (AOS):
-
Exceptional disinfection performance with concurrent decontamination
-
Ultra low energy consumption
-
Lower costs than competitors (OPEX and CAPEX)
-
Modular - Flexible - Scalable
Click HERE to learn more
BIOLARGO ENVIRONMENTAL GROUP
President:
Randall Moore
Flagship product:
Aqueous Electrostatic Concentrator
-
Cost- and energy-efficient elimination of per- and polyfluoroalkyl substances (PFAS) from contaminated water
-
More affordable than carbon-based sequestration
-
Solution huge, pressing need for effective PFAS treatment globally
Click HERE to learn more
President:
Joseph Provenzano
Flagship product:
CupriDyne Clean Industrial Odor and VOC Eliminator:
-
Eliminates odors; doesn't mask them
-
Non-toxic, non-sensitizing, non-fragranced
-
Effective against VOCs, ammonia, sulfur compounds, mercaptans, fatty acids
-
Misting systems: design, build, install, maintain, service options available
Click HERE to learn more
Minority Interest Medical Technologies Subsidiary:
.jpg)
President:
Steve Harrison
Clyra Advanced Wound Care Products:
-
Infection control, chronic wound therapy, regenerative tissue therapy
-
Non-cytotoxic, safe, broad-spectrum antimicrobial action. Efficacy proven.
-
No bacterial resistance.
-
Hydrogels, dressings, liquids
-
First product FDA 510(k) cleared
Click HERE to learn more
BioLargo Blog
BioLargo Corporate Deck
Want to learn more about BioLargo, Inc. and its subsidiaries? A great place to learn more is our corporate deck from our most recent quarterly earnings call, which you can download by clicking the button below.
Please visit the company's SEC filings page (in "Investor Relations") for the most complete company information.
